YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection

References

• Kumagai J, Komiya Y, Tanaka J, Katayama K, Tatsukawa Y, Yorioka N, Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol 2005;45:498–502.
   Google Scholar
• Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002;51:429–33.
   PubMedGoogle Scholar
• Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005;5:1452–61.
   PubMed Web of Science ®Google Scholar
• Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257–63.
   PubMedGoogle Scholar
• Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002;17:129–33.
   PubMedGoogle Scholar
• Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005;5:2433–40.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006;24:1413–22.
   PubMedGoogle Scholar
• Yasumura T, Nakajima H, Hamashima T, Nakai I, Yoshimura N, Ohmori Y, Long-term outcome of recombinant INF-alpha treatment of chronic hepatitis C in kidney transplant recipients. Transplant Proc 1997;29: 784–6.
   PubMedGoogle Scholar
• Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Wing Ho Y, Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003;39:875–8.
   PubMedGoogle Scholar
• Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D, Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol Dial Transplant 1995;10:93–6.
   PubMedGoogle Scholar
• Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004;77:1894–6.
   PubMedGoogle Scholar
• Durlik M, Gaciong Z, Rowinska D, Rancewicz Z, Lewandowska D, Kozlowska B, Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998;11:S135–9.
   Google Scholar
• Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998;66:1254–8.
   PubMedGoogle Scholar
• Bravo AA, Sheth SG, Chopra S. Liver biopsy N Engl J Med. 2001;344:495–500.
   PubMed Web of Science ®Google Scholar
• Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614–8.
   PubMed Web of Science ®Google Scholar
• Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003;38:427–32.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–57.
   PubMed Web of Science ®Google Scholar
• Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003;38:1356–8.
   PubMed Web of Science ®Google Scholar
• Montazeri G, Estakhri A, Mohamadnejad M, Nouri N, Montazeri F, Mohammadkani A, Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005;5:32.
   PubMed Web of Science ®Google Scholar
• Trocme C, Leroy V, Sturm N, Hilleret MN, Bottari S, Morel F, Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat 2006;13:643–51.
   PubMedGoogle Scholar
• Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998;5:187–92.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911–20.
   PubMed Web of Science ®Google Scholar
• Zheng M, Cai WM, Weng HL, Liu RH. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol 2002;8:1073–76.
   PubMed Web of Science ®Google Scholar
• Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ, Sampaio JP, Medina-Pestana JO, Lanzoni VP, Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat 2008;15:666–74.
   PubMedGoogle Scholar
• Laurent TC, Laurent UB, Fraser JR. Serum hyaluronan as a disease marker. Ann Med 1996;28:241–53.
   PubMed Web of Science ®Google Scholar
• Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172–209.
   PubMed Web of Science ®Google Scholar
• Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Pinheiro SR, Barbosa DV, Lanzoni VP, Prediction of Significant Liver Fibrosis in Kidney Transplant Patients with Chronic Hepatitis C Virus (HCV) Infection: the TX-3 Index. J Viral Hepat 2009, in press.
   Google Scholar
• Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839–43.
   PubMed Web of Science ®Google Scholar
• Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007;53:1615–22.
   PubMed Web of Science ®Google Scholar
• Cottone S, Palermo A, Vaccaro F, Raspanti F, Buscemi B, Incalcaterra F, In renal transplanted patients inflammation and oxidative stress are interrelated. Transplant Proc 2006;38:1026–30.
   PubMedGoogle Scholar
• Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16:3015–26.
   PubMed Web of Science ®Google Scholar
• Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005;40:538–44.
   PubMed Web of Science ®Google Scholar
• Zheng M, Cai WM, Zhao JK, Zhu SM, Liu RH. Determination of serum levels of YKL-40 and hyaluronic acid in patients with hepatic fibrosis due to schistosomiasis japonica and appraisal of their clinical value. Acta Trop 2005;96:148–52.
   PubMed Web of Science ®Google Scholar
• Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179–86.
   PubMed Web of Science ®Google Scholar
• Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476–81.
   PubMed Web of Science ®Google Scholar
• Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007;46:620–27.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Moller S, Price PA, Bendtsen F, Junge J, Garbarsch C, Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32:582–90.
   PubMed Web of Science ®Google Scholar
• Fehr T, Riehle HM, Nigg L, Gruter E, Ammann P, Renner EL, Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis 2003;42:193–201.
   PubMedGoogle Scholar
• Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005;4:6.
   PubMedGoogle Scholar
• Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935–42.
   PubMed Web of Science ®Google Scholar
• Westin J, Lagging LM, Wejstal R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999;19:183–7.
   PubMedGoogle Scholar